All Stories

  1. The Effects of Past COVID-19 and Vaccination on Antibody Levels, Cellular Immunity, and Cytokine Production by Peripheral Blood Mononuclear Cells

    Article • Biomedicines, April 2026, MDPI AG

    Dr Yulia A Desheva

  2. The Effects of Past COVID-19 and Vaccination on Antibody Levels, Cellular Immunity, and Cytokine Production by Peripheral Blood Mononuclear Cells

    Article • February 2026, MDPI AG

    Dr Yulia A Desheva

  3. Recombinant influenza A/H1N1pdm09 vaccine expressing streptococcal surface epitope for dual protection

    Article • Exploration of Immunology, November 2025, Open Exploration Publishing

    Dr Yulia A Desheva

  4. The Persistence of Cross-Reactive Immunity to Influenza B/Yamagata Neuraminidase Despite the Disappearance of the Lineage: Structural and Serological Evidence

    Article • International Journal of Molecular Sciences, August 2025, MDPI AG

    Dr Yulia A Desheva

  5. The Clinical and Laboratory Landscape of COVID-19 During the Initial Period of the Pandemic and at the Beginning of the Omicron Era

    Article • Viruses, March 2025, MDPI AG

    Dr Yulia A Desheva

  6. The Clinical and Laboratory Landscape of COVID-19 During the Initial Period of the Pandemic and at the Beginning of the Omicron Era

    Article • March 2025, MDPI AG

    Dr Yulia A Desheva

  7. Cytokine profiles and neurological manifestations in post-COVID syndrome

    Article • Exploration of Immunology, February 2025, Open Exploration Publishing

    Dr Yulia A Desheva

  8. Biological properties of the recombinant influenza A/H1N1pdm09 virus expressing a fragment of the <i>Streptococcus pneumoniae</i> surface protein

    Article • Medical academic journal, December 2024, ECO-Vector LLC

    Dr Yulia A Desheva

  9. Experimental study of early protective action of live influenza vaccine against heterologous influenza infection

    Article • Medical academic journal, December 2024, ECO-Vector LLC

    Dr Yulia A Desheva

  10. Vitral assessment of mast cells degranulation mediated by IgG antibodies

    Article • Medical academic journal, December 2024, ECO-Vector LLC

    Dr Yulia A Desheva

  11. Neuraminidase Antibody Response to Homologous and Drifted Influenza A Viruses After Immunization with Seasonal Influenza Vaccines

    Article • Vaccines, November 2024, MDPI AG

    Dr Yulia A Desheva

  12. Neuraminidase Antibody Response to Homologous and Drift Influenza a Viruses After Immunization with Seasonal Influenza Vaccines

    Article • October 2024, MDPI AG

    Dr Yulia A Desheva

  13. Comparative Efficacy of Parenteral and Mucosal Recombinant Probiotic Vaccines Against SARS-CoV-2 and S. pneumoniae Infections in Animal Models

    Article • Vaccines, October 2024, MDPI AG

    Dr Yulia A Desheva

  14. Exploring immune response and lab markers across COVID-19 severity levels

    Article • AIMS Allergy and Immunology, January 2024, American Institute of Mathematical Sciences (AIMS)

    Dr Yulia A Desheva

  15. Exploring Immune Response and Lab Markers Across COVID-19 Severity Levels

    Article • December 2023, MDPI AG

    Dr Yulia A Desheva

  16. Evaluation of Immune Response to Mucosal Immunization with an Oral Probiotic-Based Vaccine in Mice: Potential for Prime-Boost Immunization against SARS-CoV-2

    Article • International Journal of Molecular Sciences, December 2023, MDPI AG

    Dr Yulia A Desheva

  17. Immune response and laboratory markers in the spectrum of severity of COVID-19

    Article • Medical academic journal, December 2023, ECO-Vector LLC

    Dr Yulia A Desheva

  18. Longitudinal Analysis of Neuraminidase and Hemagglutinin Antibodies to Influenza A Viruses after Immunization with Seasonal Inactivated Influenza Vaccines

    Article • Vaccines, November 2023, MDPI AG

    Dr Yulia A Desheva

  19. SARS-CoV-2 Spike Protein-Expressing Enterococcus for Oral Vaccination: Immunogenicity and Protection

    Article • Vaccines, November 2023, MDPI AG

    Dr Yulia A Desheva

  20. SARS-CoV-2 Spike Protein-Expressing Enterococcus for Oral Vaccination: Immunogenicity and Protection

    Article • October 2023, MDPI AG

    Dr Yulia A Desheva

  21. Longitudinal Analysis of Neuraminidase Antibodies to Influenza a Viruses after Immunization with Seasonal Inactivated Influenza Vaccines

    Article • September 2023, MDPI AG

    Dr Yulia A Desheva

  22. Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity

    Article • Antibodies, February 2023, MDPI AG

    Dr Yulia A Desheva

  23. Establishment of a Pseudovirus Platform for Neuraminidase Inhibiting Antibody Analysis

    Article • International Journal of Molecular Sciences, January 2023, MDPI AG

    Dr Yulia A Desheva

  24. Detection of immunoglobulins specific to SARS-CoV-2 virus S-protein in mixed saliva

    Article • Medical academic journal, November 2022, ECO-Vector LLC

    Dr Yulia A Desheva

  25. Surface expression of SARS-CoV-2 epitopes in <i>Enterococcus faecium</i> L3 for live oral vaccine against new coronavirus infection

    Article • Medical academic journal, November 2022, ECO-Vector LLC

    Dr Yulia A Desheva

  26. Antigenic Characterization of Neuraminidase of Influenza A/H7N9 Viruses Isolated in Different Years

    Article • Pharmaceuticals, September 2022, MDPI AG

    Dr Yulia A Desheva

  27. Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in Mice

    Article • Microorganisms, June 2022, MDPI AG

    Dr Yulia A Desheva

  28. Study of Antibodies to Influenza Neuraminidase N2

    Article • Pharmaceuticals, April 2022, MDPI AG

    Dr Yulia A Desheva

  29. Associated virus-bacterial vaccine based on seasonal LAIV and S. pneumoniae chimeric peptide provide protection against post-influenza pneumococcal infection in mouse model

    Article • Virulence, March 2022, Taylor & Francis

    Dr Yulia A Desheva

  30. Prospects of using conservative linear B-cell epitopes of influenza virus A neuraminidase for induction of cross-protective immune response

    Article • Medical academic journal, December 2021, ECO-Vector LLC

    Dr Yulia A Desheva

  31. The role of coinfection with influenza viruses in the pathogenesis of severe infection in patients with COVID-19

    Article • Medical academic journal, December 2021, ECO-Vector LLC

    Dr Yulia A Desheva

  32. Developing a Live Probiotic Vaccine Based on the Enterococcus faecium L3 Strain Expressing Influenza Neuraminidase

    Article • Microorganisms, November 2021, MDPI AG

    Dr Yulia A Desheva

  33. Study of Antibody-Dependent Reactions of Mast Cells In Vitro and in a Model of Severe Influenza Infection in Mice

    Article • Frontiers in Immunology, July 2021, Frontiers

    Dr Yulia A Desheva

  34. Evaluation of influenza A and B cold-adapted reassortant virus reproduction in trivalent live influenza vaccines

    Article • Virus Research, July 2021, Elsevier

    Dr Yulia A Desheva

  35. Assessment of trivalent live influenza vaccines in MDCK cell line

    Article • MethodsX, January 2021, Elsevier

    Dr Yulia A Desheva

  36. Mast cell degranulation and histamine release during A/H5N1 influenza infection in influenza-sensitized mice

    Article • Life Sciences, October 2020, Elsevier

    Dr Yulia A Desheva

  37. Study of Neuraminidase-Inhibiting Antibodies in Clinical Trials of Live Influenza Vaccines

    Article • Antibodies, May 2020, MDPI AG

    Dr Yulia A Desheva

  38. The prevalence of conjunctivitis in patients with novel coronavirus (COVID-19) and preventive measures

    Article • Russian Journal of Clinical Ophthalmology, January 2020, LLC Russian Medical Journal

    Dr Yulia A Desheva

  39. Contribution of antibody-dependent enhancement to the pathogenesis of coronavirus infections

    Article • AIMS Allergy and Immunology, January 2020, American Institute of Mathematical Sciences (AIMS)

    Dr Yulia A Desheva

  40. Combined immunization with attenuated live influenza vaccine and chimeric pneumococcal recombinant protein improves the outcome of virus-bacterial infection in mice

    Article • PLOS One, September 2019, PLOS

    Dr Yulia A Desheva, GALINA LEONTEVA

  41. INDUCTION OF CROSS-REACTIVE ANTIBODIES IN MICE IMMUNIZED WITH CONSERVED LINEAR B-CELL EPITOPES DERIVED FROM INFLUENZA A VIRUS NEURAMINIDASE

    Article • Russian Journal of Infection and Immunity, June 2019, SPb RAACI

    Dr Yulia A Desheva

  42. Mucosal vaccine based on attenuated influenza virus and the group B Streptococcus recombinant peptides protected mice from influenza and S. pneumoniae infections

    Article • PLOS One, June 2019, PLOS

    Dr Yulia A Desheva

  43. Introductory Chapter: Human Adenoviruses

    Article • March 2019, IntechOpen

    Dr Yulia A Desheva

  44. Adenoviruses

    Article • March 2019, IntechOpen

    Dr Yulia A Desheva

  45. Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection

    Article • Heliyon, February 2019, Elsevier

    Dr Yulia A Desheva

  46. Preparing Live Influenza Vaccines against Potential Pandemic Influenza Using Nonpathogenic Avian Influenza Viruses and Cold-Adapted Master Donor Strain

    Article • September 2018, IntechOpen

    Dr Yulia A Desheva

  47. Anti–Influenza Activity of Enterocin B In vitro and Protective Effect of Bacteriocinogenic Enterococcal Probiotic Strain on Influenza Infection in Mouse Model

    Article • Probiotics and Antimicrobial Proteins, August 2018, Springer Science + Business Media

    Dr Yulia A Desheva

  48. Anti-neuraminidase antibodies against pandemic A/H1N1 influenza viruses in healthy and influenza-infected individuals

    Article • PLOS One, May 2018, PLOS

    Dr Yulia A Desheva

  49. Prevention of Influenza A(H7N9) and Bacterial Infections in Mice Using Intranasal Immunization With Live Influenza Vaccine and the Group B Streptococcus Recombinant Polypeptides

    Article • Virology Research and Treatment, January 2017, SAGE Publications

    Dr Yulia A Desheva, Prof. Alexander N Suvorov

  50. Baculovirus as a platform for the anchorage of hemagglutinin from influenza virus

    Article • Journal of Immunological Techniques in Infectious Diseases, January 2017, OMICS Publishing Group

    Dr Yulia A Desheva

  51. The crystal structure of an orthomyxovirus matrix protein reveals mechanisms for self-polymerization and membrane association

    Article • Journal of Immunological Techniques in Infectious Diseases, January 2017, OMICS Publishing Group

    Dr Yulia A Desheva

  52. Evaluation in Mouse Model of Combined Virus-bacterial Vaccine Based on Attenuated Influenza A(H7N3) Virus and the Group B Streptococcus Recombinant Polypeptides

    Article • The Open Microbiology Journal, October 2016, Bentham Science Publishers

    Dr Yulia A Desheva, Prof. Alexander N Suvorov

  53. Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers

    Article • BMC Research Notes, April 2015, Springer Science + Business Media

    Dr Yulia A Desheva

  54. Live Attenuated Influenza H7N3 Vaccine is Safe, Immunogenic and Confers Protection in Animal Models

    Article • The Open Microbiology Journal, January 2015, Bentham Science Publishers

    Dr Yulia A Desheva

  55. Assessment of Human Immune Responses to H7 Avian Influenza Virus of Pandemic Potential: Results from a Placebo–Controlled, Randomized Double–Blind Phase I Study of Live Attenuated H7N3 Influenza Vaccine

    Article • PLOS One, February 2014, PLOS

    Dr Yulia A Desheva

  56. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza

    Article • Influenza and Other Respiratory Viruses, November 2008, Wiley

    Dr Yulia A Desheva

  57. 6-sulfo sialyl Lewis X is the common receptor determinant recognized by H5, H6, H7 and H9 influenza viruses of terrestrial poultry

    Article • Virology Journal, January 2008, Springer Science + Business Media

    Dr Yulia A Desheva

  58. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential

    Article • Vaccine, November 2006, Elsevier

    Dr Yulia A Desheva

  59. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses

    Article • Vaccine, November 2006, Elsevier

    Dr Yulia A Desheva

  60. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents

    Article • Vaccine, September 2000, Elsevier

    Dr Yulia A Desheva